98 results about "Bile Duct Carcinoma" patented technology

The invention belongs to the field of genetic engineering and in particular relates to an application of a bile exosome long and non-coding RNA (lncRNA) ENST00000588480.1 in diagnosis of bile duct carcinoma, prognostic prediction and target spot drug treatment, wherein the long and non-coding RNA is positively correlated with TNM staging and poor prognosis of a patient.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

This document relates to methods and materials involved in assessing isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutations in a mammal (e.g., human). For example, this document provides methods and materials for diagnosis, characterization, determining prognosis, and treatment of cholangiocarcinoma tumor in a mammal.

The invention discloses application of CLEC1B (C-type lectin domain family 1 member B) genes on diagnosis and treatment of bile duct carcinoma. RNA (ribonucleic acid)-sep screening is carried out, and a large sample RT-PCR (reverse transcription-polymerase chain reaction) proves that CLEC1B gene expression abnormality is related to initiation and development of the bile duct carcinoma. According to a research result, CLEC1B can also be used for preparing medicines for treating the bile duct carcinoma. By the application of the CLEC1B genes on diagnosis and treatment of the bile duct carcinoma, sensitivity and specificity of diagnosis of the bile duct carcinoma are greatly improved, and a new target spot is provided for gene therapy of the bile duct carcinoma.

The invention discloses application of a PZP gene in diagnosis and treatment of a biliary duct cancer. The PZP gene is low-expressed in tissue of a biliary duct cancer patient, and growth and invasion of biliary duct cancer cells can be restrained by increasing expression of PZP. According to the application of the PZP gene in the diagnosis and treatment of the biliary duct cancer, the sensibility and the specificity of biliary duct cancer diagnosis are greatly improved, and meanwhile a new target site is provided for gene treatment of the biliary duct cancer.

The present disclosure provides a method of treating a biliary duct cancer, such as cholangiocarcinoma, by administering a therapeutically effective amount of a compound of formula (I), in particular Varlitinib, an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same.

The invention discloses a culture medium for culturing primary cells related to cholecystic cholangiocarcinoma. The culture medium for culturing primary cells related to cholecystic cholangiocarcinoma is a special serum-free culture medium. The culture medium is used for carrying out in-vitro suspension culture on tumor cells derived from cholecystic cholangiocarcinoma, so that the interference from normal cells can be eliminated to the greatest extent while normal amplification of cancer cells is ensured. The primary cell culture of cholecystic cholangiocarcinoma obtained by the method can be used for various cellular in-vitro experiments, next-generation sequencing, construction of animal models, construction of cell lines and the like. Predictably, the culture method has a wide application prospect in the fields of research and clinical diagnosis and treatment of the cholecystic cholangiocarcinoma.

The invention relates to a cholangiocarcinoma cell medicine target point. The medicine target point is ubiquitin specific protease 8, and the nucleotide sequence is shown as SEQID NO:1 in a sequence table. For the first time, the invention puts forward that USP8 is knocked down, so that proliferation, migration and invasion of cholangiocarcinoma cells can be notably restrained, MMP9 activity achieving important effects on cell adhesion, neoplasm invasiveness and transfer is reduced, and the USP8 is promoted to achieve effect of oncogene for growth and transfer ability of cholangiocarcinoma. New possibility is provided for development of cholangiocarcinoma medicines and cholangiocarcinoma prevention, treatment and prognosis.

5′-methylthioadenosine (MTA) is described as a compound that is susceptible to inhibiting and/or blocking the epithelial-mesenchymal transition (EMT), a process whereby epithelial cells become mesenchymal cells.

The periodical intake of MTA [every 24 h for 21 days] significantly improves fibrosis and the markers for hepatic cellular damage in KO-Mdr2 mice with MTA (28 mg/kg). Following the daily oral administration of MTA, both the expression of EMT markers in the total liver and appreciable signs of fibrosis are significantly reduced, indicating the beneficial effect of MTA on the liver affected by the lack of Mdr2. MTA is proposed to be a safe drug, suitable for oral formulation and without secondary effects, to be used in the prevention and/or treatment of diseases associated with EMT, including chronic cholestatic diseases, fibrosis and cholangiocarcinoma. On the other hand, MTA is proposed for application in anti-tumor therapies by inhibiting or blocking the EMT properties of CSC cells, in order to improve the prognosis of tumor development and the malignancy thereof.

The present invention provides a method for specific sorting of CTC in serum of biliary tract tumors. An appropriate amount of peripheral blood from patients with biliary tract tumors is taken and placed in anticoagulation centrifuge tubes and whole blood samples are mixed evenly; the collected blood samples are sequentially subjected to sample processing of plasma protein and plasma nucleic acidremoval, red blood cell removal, layered centrifugation and white blood cell removal; an HSPG antibody or a SDC1 subtype antibody or a SDC2 subtype antibody or a GPC1 subtype antibody or a GPC3 subtype antibody is used to combine with immunomagnetic beads to capture HSPG positive or SDC1 positive or SDC2 positive or GPC1 positive or GPC3 positive CTC. HSPG is used as a relatively specific functional tumor molecular marker for CTC sorting of gallbladder cancer and cholangiocarcinoma, thereby improving sorting efficiency of biliary tract tumor CTC, a set of HSPG-based CTC molecular typing scoring system is established, the high-specificity and high-sensitivity detection method for the biliary tract tumors is otbained, and based on the high-efficiency sorting of the biliary tract tumor CTC, downstream RNA-seq and gene NGS detection is conducted to obtain tumor-specific molecular information to improve specificity.

The present disclosure provides a method for detecting cholangiocarcinoma cells. The capture rate of the cholangiocarcinoma cells of the present disclosure is higher than 70%, and a plurality of octasaccharides with high affinity and specificity can be modified on the surface of magnetic beads to capture and analyze cholangiocarcinoma cells under test, wherein the cholangiocarcinoma cells can be circulating tumor cells in cholangiocarcinoma.

The invention provides quinoline for treating cholangiocarcinoma, and an application thereof to preparation of a medical composition for treating tumors, and particularly relates to an application ofquinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indole -5-)oxy-6-methoxyquinolin-7-yl]oxy]methyl cyclopropylamine to treatment cholangiocarcinoma: as shown in the description.

A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.

The invention discloses a marker for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma and application of the marker. The marker for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma is CXCR3 expressed on the surfaces of peripheral blood leukocytes or immune cells in cholangiocarcinoma tissues of an intrahepatic cholangiocarcinoma patient. A kit for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma comprises a reagent related to detection of the expression quantity of the CXCR3 protein. A method for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma comprises the following steps: (1) detecting the expression quantity of CXCR3 on the surfaces of peripheral blood leukocytes or immune cells in cholangiocarcinoma tissues of an intrahepatic cholangiocarcinoma patient; and (2) comparing the expression quantity with a preset CXCR3 protein expression quantity threshold value, evaluating that the patient is sensitive to gemcitabine chemotherapy and/or good in prognosis of gemcitabine chemotherapy if the CXCR3 protein expression quantity is higher than the threshold value, and otherwise, evaluating that the patient is insensitive to gemcitabine chemotherapy and/or poor in prognosis of gemcitabine chemotherapy.

The invention discloses a traditional Chinese medicine composition for treating postoperative hepatic cholangiocarcinoma and cancerometastasis. The traditional Chinese medicine composition comprises the raw materials of rhizoma gastrodiae, radix curcumae, vinegar-processed rhizoma cyperi, fructus aurantii immaturus, ligusticum wallichii, poria with hostwood, polyporus umbellatus, endothelium corneum gigeriae galli, herba lycopi, angelica sinensis, rhizoma corydalis, radix pseudostellariae, leech, herba artemisiae scopariae, cornu bubali, amber, lumbricus, herba lysimachiae, scorched rhizoma atractylodis macrocephalae, ginseng hair, semen cuscutae, artemisia anomala, gadfly, sculellaria barbata, peach kernel, lygodium japonicum, rheum officinale, Chinese lobelia, rose, lotus root, fried jujube kernel, platycladi seed, tortoise plastron, turtle shell and radix glycyrrhizae. According to the traditional Chinese medicine composition disclosed by the invention, all the Chinese herbal medicines are subjected to a medicine composition, the transformation, reduction and extinction process of the medicine property in the mechanism of the disease and multi-directional gasification evolution are determined, and finally, cancer cells are quickly reversed into normal physiological factors of a human body.

The invention belongs to the technical field of medicines, relates to use of a fibroblast growth factor receptor inhibitor and particularly relates to a compound represented by a general formula (I) for treating cholangiocarcinoma and pharmaceutically acceptable salts and isomers thereof, a pharmaceutical composition containing the compound or pharmaceutically acceptable salts and isomers thereof, a method for treating the cholangiocarcinoma by using the compound or pharmaceutically acceptable salts and isomers thereof, use of the compound or pharmaceutically acceptable salts and isomers thereof in cholangiocarcinoma treatment and use of the compound or pharmaceutically acceptable salts and isomers thereof in preparation of drugs for treating the cholangiocarcinoma of mammals. Each variable of the general formula is as defined in the description. Shown by researches, the compound represented by the general formula (I) or pharmaceutically acceptable salts and isomers thereof has a remarkable therapeutic action on the cholangiocarcinoma and has very great clinical application potentials.